Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe psoriasis: Findings from the phase 3 POETYK PSO-3 and PSO-4 trials

被引：0

作者：

Foley, Peter ^{[1
,2
]}

Zhang, Jianzhong ^{[3
]}

Imafuku, Shinichi ^{[4
]}

Ding, Yangfeng ^{[5
]}

Okubo, Yukari ^{[6
]}

Li, Hui ^{[7
]}

Tada, Yayoi ^{[8
]}

Li, Linfeng ^{[9
]}

Ohtsuki, Mamitaro ^{[10
]}

Pan, Weili ^{[11
]}

Lu, Yan ^{[12
]}

Hao, Cheng ^{[13
]}

Xian, Jiang ^{[14
]}

Ho, Ji-Chen ^{[15
]}

Guo, Shuping ^{[16
]}

Seo, Seong Jun ^{[17
]}

Napoli, Andrew ^{[18
]}

Chatterjee, Arkendu ^{[18
]}

Kisa, Renata M. ^{[18
]}

Banerjee, Subhashis ^{[18
]}

Morita, Akimichi ^{[19
]}

机构：

[1] Univ Melbourne, St Vincents Hosp Melbourne, Prob Med Res, Melbourne, Vic, Australia

[2] Skin Hlth Inst, Melbourne, Vic, Australia

[3] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[4] Fukuoka Univ Hosp, Fukuoka, Japan

[5] Shanghai Skin Dis Hosp, Shanghai, Peoples R China

[6] Tokyo Med Univ, Tokyo, Japan

[7] Chongqing Med Univ, Affiliated Hosp 1, Shanghai, Peoples R China

[8] Teikyo Univ, Sch Med, Tokyo, Japan

[9] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[10] Jichi Med Univ, Shimotsuke, Tochigi, Japan

[11] Peoples Hosp Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China

[12] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China

[13] Zhejiang Univ, Sir Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China

[14] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[15] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan

[16] Shanxi Med Univ, Hosp 1, Jinzhong, Shanxi, Peoples R China

[17] Chung Ang Univ Hosp, Seoul, South Korea

[18] Bristol Myers Squibb, New York, NY USA

[19] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Japan

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：28 / 29

页数：2

共 50 条

[1] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor: Improvement in scalp psoriasis in the phase 3 POETYK PSO-3 trial in Asian patients
Zhang, J.
Ding, Y.
Wang, P.
Li, L.
Pan, W.
Lu, Y.
Liu, L.
Kisa, R. M.
Hoyt, K.
Banerjee, S.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S108 - S108
[2] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Improvement in body surface area involvement in the phase 3 POETYK PSO-3 trial
Zhang, J.
Ding, Y.
Wang, P.
Li, L.
Pan, W.
Lu, Y.
Liu, L.
Kisa, R. M.
Hoyt, K.
Banerjee, S.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S109 - S109
[3] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial
Imafuku, Shinichi
Okubo, Yukari
Tada, Yayoi
Ohtsuki, Mamitaro
Shao, Yanqiu
Colston, Elizabeth
Kisa, Renata M.
Banerjee, Subhashis
Morita, Akimichi
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
[4] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Gooderham, Melinda
Spelman, Lynda
Imafuku, Shinichi
Romanelli, Marco
Merola, Joseph F.
Armstrong, April W.
Colston, Elizabeth
Banerjee, Subhashis
Scharnitz, Thomas
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
[5] DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MODERATE TO SEVERE PLAQUE PSORIASIS: 52-WEEK EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 TRIALS
Warren, R. B.
Armstrong, A.
Gooderham, M.
Strober, B.
Thaci, D.
Imafuku, S.
Sofen, H.
Spelman, L.
Korman, N. J.
Zheng, M.
Colston, E.
Throup, J.
Kundu, S.
Kisa, R.
Banerjee, S.
Blauvelt, A.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1570 - 1571
[6] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
Eisman, Samantha
Blauvelt, Andrew
Rich, Phoebe
Sofen, Howard
Lambert, Jo
Merola, Joseph
Lebwohl, Mark
Scharnitz, Thomas
Hoyt, Kim
Kisa, Renata M.
Banerjee, Subhashis
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 51 - 51
[7] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
Warren, Richard B.
Armstrong, April W.
Imafuku, Shinichi
Paul, Carle
Kircik, Leon
Colston, Elizabeth
Scharnitz, Thomas
Wang, Tao
Banerjee, Subhashis
Strober, Bruce
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
[8] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials
Spelman, Lynda
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 66 - 66
[9] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate/severe plaque psoriasis: onset of action in the phase 3 POETYK PSO-1 and PSO-2 trials
Foley, Peter
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 65 - 65
[10] Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials
Morita, Akimichi
Imafuku, Shinichi
Tada, Yayoi
Okubo, Yukari
Habiro, Katsuyoshi
Tsuritani, Katsuki
Banerjee, Subhashis
Hoyt, Kim
Kisa, Renata M.
Ohtsuki, Mamitaro
JOURNAL OF DERMATOLOGY, 2025,

← 1 2 3 4 5 →